Attorney Docket No. 100717-687 KGB CONFIRMATION NO. 2486

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT · Daniel RUDHARDT et al.

SERIAL NO. : 10/583,302

CUSTOMER NO. : 27384

FILED : August 14, 2006

FOR : MULTIPHASE ACTIVE INGREDIENT FORMULATION

ART UNIT : 1614

EXAMINER : To Be Assigned

Commissioner for Patents

PO Box 1450

SIR:

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO/SB/08.

I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

II. Copies of Listed References

Copies of all references listed on the attached Form PTO/SB/08 are being supplied. Copies

of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

III. Concise Statement of Relevance

All references listed on the attached Form PTO/SB/08 are referred to in the specification which indicates the degree of relevance.

The Examiner will note that English language counterparts or Abstracts of non-English language references are also enclosed, as follows:

DE 10 50 382 A1 - Cited on page 2 of the specification. Abstract provided.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCL'AUGHLIN & MARCUS, P.A.

By _

Kurt G. Briscoe Attorney for Applicant(s) Reg. No. 33,141 875 Third Avenue - 18th Floor New York, New York 10022

Phone: (212) 808-0700 Fax: (212) 808-0844